Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Neoplasms | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
AR(Androgen Receptor) | 1 |
Lipid x Triglyceride | 1 |
Target |
Mechanism Lipid modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date10 Nov 2004 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date29 Sep 2020 |
Sponsor / Collaborator |
Start Date05 Aug 2020 |
Sponsor / Collaborator |
Start Date20 Feb 2020 |
Sponsor / Collaborator ![]() [+2] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Omega-3-acid ethyl esters(Trygg Pharma AS) ( Lipid x Triglyceride ) | Cardiovascular Diseases More | Phase 3 |
US20240390413 Patent Mining | Infectious Diseases More | Discovery |
IL289744 ( AR )Patent Mining | Infectious Diseases More | Discovery |
Icosabutate ( CETP x GPR120 ) | Dyslipidemias More | Discontinued |
Emopamil ( P-gp ) | Migraine Disorders More | Discontinued |